Biokine Technology

Biokine Therapeutics is a clinical-stage biopharmaceutical company based in Israel that specializes in the development of novel therapeutics targeting cancer and inflammation. The company is best known for its lead product, BKT140 (also known as BL-8040 or motixafortide), a high-affinity CXCR4 antagonist that has been successfully developed for stem cell mobilization and various oncology indications. Motixafortide, marketed as Aphexda, received FDA approval in 2023 for use in combination with filgrastim to mobilize hematopoietic stem cells for collection and subsequent autologous transplantation in patients with multiple myeloma. Biokine utilizes its proprietary discovery platforms, MigHit™ and ImmunHit™, to identify small molecules that selectively inhibit the migration and survival of cancer cells. The company maintains a strong partnership with BioLineRx, which holds the global license for the clinical development and commercialization of motixafortide.